Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

NIH 7OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Prostatic Neoplasms 56Lung Neoplasms 48Leukemia, Myeloid, Acute 44Breast Neoplasms 37Carcinoma, Non-Small-Cell Lung 36Myelodysplastic Syndromes 27Pancreatic Neoplasms 24Leukemia, Lymphocytic, Chronic, B-Cell 24Multiple Myeloma 23Colorectal Neoplasms 23Carcinoma, Renal Cell 22Neoplasm Metastasis 20Melanoma 20Glioblastoma 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Ovarian Neoplasms 17Lymphoma, Large B-Cell, Diffuse 17Brain Neoplasms 16Triple Negative Breast Neoplasms 14Squamous Cell Carcinoma of Head and Neck 12Carcinoma, Hepatocellular 12Lymphoma, Mantle-Cell 11Lymphoma, B-Cell 11Leukemia, Myelomonocytic, Chronic 11Fallopian Tube Neoplasms 11Rectal Neoplasms 10Myeloproliferative Disorders 10Lymphoma, Follicular 10Colonic Neoplasms 10Hematopoietic and Lymphatic System Neoplasm 9

Interventions

Gemcitabine 82Cisplatin 52Oxaliplatin 36lenvatinib 24durvalumab 22Capecitabine 22Fluorouracil 20Leucovorin 15tislelizumab 11pembrolizumab 10apatinib 10Radiotherapy 10Albumin-Bound Paclitaxel 10Radiofrequency Ablation 9Magnetic Resonance Spectroscopy 9Irinotecan 9Floxuridine 9Liver Transplantation 8Drug Therapy 8Cholangiopancreatography, Endoscopic Retrograde 8130-nm albumin-bound paclitaxel 8Taxes 7Platinum 7Photochemotherapy 7Panitumumab 7Biopsy 71,2-diaminocyclohexaneplatinum II citrate 7tremelimumab 6pemigatinib 6camrelizumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Cholangiocarcinoma × Specimen Handling × Clear all
NCT06058663 2026-05-13

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Mayo Clinic

Phase 1 Recruiting
16 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT03942328 2026-04-20

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Mayo Clinic

Phase 1/2 Recruiting
85 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT06178588 2026-02-24

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

University of Kansas Medical Center

Phase 2 Active not recruiting
15 enrolled
Gastrointestinal

Cholangiocarcinoma, Klatskin Tumor

NCT06420349 2025-12-22

NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

Mayo Clinic

Phase 1 Terminated
7 enrolled
Gastrointestinal

Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡